|
|||||
|
|
Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week,Multicenter, Randomized,Double‐Blind,Placebo‐Controlled Study with a 28‐Week Extension |
|
| Authors: | Lawrence A. Leiter MD William T. Cefalu MD Tjerk W. A. de Bruin MD PhD Ingrid Gause‐Nilsson MD PhD Jennifer Sugg MS Shamik J. Parikh MD |
| Affiliation: | 1. Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, , Toronto, Ontario, Canada;2. Division of Endocrinology and Metabolism, University of Toronto, , Toronto, Ontario, Canada;3. Pennington Biomedical Research Center, Louisiana State University System, , Baton Rouge, Louisiana;4. Research and Development, AstraZeneca, , Wilmington, Delaware;5. Research and Development, AstraZeneca, , M?lndal, Sweden |
| Abstract: | |
| Keywords: | dapagliflozin SGLT2 inhibitor comorbidities cardiovascular comorbidities type 2 diabetes mellitus |